Last reviewed · How we verify
Live attenuated influenza virus
Live attenuated influenza virus vaccine stimulates immune responses by delivering weakened virus that replicates in the respiratory tract without causing severe disease.
Live attenuated influenza virus vaccine stimulates immune responses by delivering weakened virus that replicates in the respiratory tract without causing severe disease. Used for Influenza prevention in pediatric and adult populations.
At a glance
| Generic name | Live attenuated influenza virus |
|---|---|
| Sponsor | Turku University Hospital |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains live influenza virus strains that have been attenuated (weakened) through laboratory passage to reduce virulence while maintaining immunogenicity. Upon intranasal administration, the attenuated virus replicates in the upper respiratory epithelium, triggering both mucosal and systemic immune responses including antibody production and T-cell activation. This approach mimics natural infection while avoiding the complications of wild-type influenza.
Approved indications
- Influenza prevention in pediatric and adult populations
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
- Headache
- Muscle aches
Key clinical trials
- Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD) (EARLY_PHASE1)
- Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine (PHASE1)
- Durability of Vaccine Responses (PHASE4)
- Woodsmoke Exposure, Influenza Infection, and Nasal Immunity (PHASE4)
- GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE (NA)
- Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine (PHASE4)
- The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students (PHASE4)
- Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Live attenuated influenza virus CI brief — competitive landscape report
- Live attenuated influenza virus updates RSS · CI watch RSS
- Turku University Hospital portfolio CI